Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EW vs BSX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BSX Captures Overall Composite Edge (58.8 HOLD vs 31.5 SELL), While EW Leads 4–2 on Growth & Valuation Pillars
BSX Overall Winner
6-Pillar Tally: EW 4 – 2 BSX
Matrix Metrics: EW 4 – 6 BSX
As of Nov 16, 2026, Boston Scientific Corp. (BSX) captures the overall head-to-head institutional edge over Edwards Lifesciences Corp (EW) on higher Unified Composite conviction (58.8/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while EW wins 4–2 across the 6-pillar growth and valuation breakdown. EW trades at $106.66 (31.6x Forward P/E, 28.8% operating margin) versus BSX at $43.74 (14.2x Forward P/E, 19.6% operating margin).
- Growth vs. Quality Trade-Off: BSX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. EW 31.5/100 SELL) and 0.32β · 45% Vol risk profile, whereas EW leads top-line expansion (+10.5% YoY revenue growth, 2.33x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EW vs BSX
EW
Edwards Lifesciences Corp
$106.66
-0.46% 1D
Market Cap
$60.8B
TTM Revenue
$6.67B
Forward P/E
31.6x
Beta / 30D Vol
0.44β · 24% Vol
Unified Composite Score
31.5
SELL
Tech 50.0
Fund 29.0
Flow 51.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
BSX
Head-to-Head Winner
Boston Scientific Corp.
$43.74
-1.35% 1D
Market Cap
$64.1B
TTM Revenue
$21.1B
Forward P/E
14.2x
Beta / 30D Vol
0.32β · 45% Vol
Unified Composite Score
58.8
HOLD
Tech 49.0
Fund 58.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 BSX)
1. Valuation Multiples
BSX
Forward P/E
31.6x
14.2x
Trailing P/E
61.5x
18.6x
PEG Ratio
2.33x
0.76x
EV / Revenue
8.8x
3.6x
2. Growth & Scale
EW
Revenue Growth (YoY)
+10.5%
+1.4%
Earnings Growth (YoY)
+6.7%
-21.5%
TTM Revenue (USD)
$6.67B
$21.1B
Market Cap
$60.8B
$64.1B
3. Profitability & Quality
EW
Gross Margin
78.0%
68.0%
Operating Margin
28.8%
19.6%
Net Profit Margin
15.3%
16.6%
Return on Equity (ROE)
9.3%
14.1%
4. Balance Sheet & Cash Flow
EW
Cash Generation (TTM)
$1.42B
$1.46B
Cash Flow Margin
21.3%
6.9%
Net Cash / Leverage
$2.41B Net Cash
$11.3B Net Debt (0.47x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BSX
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
24.6% (34th %ile)
77.2% (53rd %ile)
Put/Call OI Skew
N/A
1.01x (Balanced)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
EW
OpEx & R&D Intensity
49.2% of Rev ($3.28B)
48.4% of Rev ($10.2B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EW (4) vs BSX (6)| Institutional Metric | EW | BSX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $60.8B | $64.1B | BSX | |
| Trailing P/E Ratio | 61.5x | 18.6x | BSX | |
| Forward P/E Ratio | 31.6x | 14.2x | BSX | |
| Revenue Growth (YoY) | +10.5% | +1.4% | EW | |
| Operating Margin (TTM) | 28.8% | 19.6% | EW | |
| Net Profit Margin | 15.3% | 16.6% | BSX | |
| Return on Equity (ROE) | 9.3% | 14.1% | BSX | |
| 52-Week Range Position | 96% ($75–$108) | 6% ($40–$106) | EW | |
| Beta / 30D Volatility | 0.44β · 24% Vol | 0.32β · 45% Vol | EW | |
| Unified Institutional Score | 31.5 / 100 (SELL) | 58.8 / 100 (HOLD) | BSX | |
| Trailing 12M Revenue (USD) | $6.67B | $21.1B | Scale | |
| Gross Profit Margin (TTM) | 78.0% | 68.0% | Quality | |
| PEG Ratio & EV / Revenue | 2.33x PEG · 8.8x EV/Rev | 0.76x PEG · 3.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.42B ($2.41B Net Cash) | $1.46B ($11.3B Net Debt (0.47x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EW +24.62 pp
3M Horizon
EW +30.56 pp
6M Horizon
EW +51.23 pp
1Y Horizon
EW +82.19 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EW Revenue | BSX Revenue | EW Op. Margin | BSX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $3.72B | $9.82B | 20.1% | 15.3% | EW |
| FY2019 | $4.35B | $10.7B | 26.4% | 14.1% | EW |
| FY2020 | $4.39B | $9.91B | 20.5% | -0.8% | EW |
| FY2021 | $5.23B | $11.9B | 32.3% | 10.1% | EW |
| FY2022 | $4.46B | $12.7B | 33.6% | 13.0% | EW |
| FY2023 | $5.01B | $14.2B | 26.1% | 16.5% | EW |
| FY2024 | $5.44B | $16.8B | 25.3% | 15.5% | EW |
| FY2025 | $6.07B | $20.1B | 20.8% | 18.0% | EW |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EW
UNCLASSIFIED
Current IV
24.6%
IV Percentile
34th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BSX
CONSOLIDATION
Current IV
77.2%
IV Percentile
53rd %ile
Put/Call OI Skew
1.01x (Balanced)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BSX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EW Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
49.2% of Rev ($3.28B)
90D Engineering Disclosures
0 Published
BSX Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
48.4% of Rev ($10.2B)
90D Engineering Disclosures
0 Published
Investor FAQ EW vs BSX Key Questions & Quantitative Answers
As of Nov 16, 2026, Boston Scientific Corp. (BSX) captures the overall head-to-head institutional edge over Edwards Lifesciences Corp (EW) on higher Unified Composite conviction (58.8/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while EW wins 4–2 across the 6-pillar growth and valuation breakdown. EW trades at $106.66 (31.6x Forward P/E, 28.8% operating margin) versus BSX at $43.74 (14.2x Forward P/E, 19.6% operating margin). Growth vs. Quality Trade-Off: BSX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. EW 31.5/100 SELL) and 0.32β · 45% Vol risk profile, whereas EW leads top-line expansion (+10.5% YoY revenue growth, 2.33x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with BSX at +1.4% YoY revenue growth and -21.5% YoY earnings growth on $21.1B TTM revenue (68.0% gross margin, 19.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while BSX shifted +104.4%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 48.4% of Rev ($10.2B) (0 disclosures) for BSX.
BSX screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas BSX trades at 14.2x Forward P/E, 18.6x Trailing P/E, 0.76x PEG, and 3.6x EV/Revenue (6.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus BSX (14.1% ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, BSX carries 77.2% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 1.01x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BSX vs EW · Reverse Pair
EW vs BAX
· Sector Peer
EW vs RMD
· Sector Peer
EW vs SYK
· Sector Peer
BSX vs MDT
· Sector Peer
BSX vs SYK
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem